Sudeep Pharma Limited has completed its Q2FY26 results presentation and earnings call, subsequently submitting the audio recording to stock exchanges in compliance with regulatory requirements. The pharmaceutical company conducted its earnings discussion on December 22, 2025, as previously scheduled.

Earnings Call Completion

The company successfully held its Q2FY26 earnings call on Monday, December 22, 2025, at 11:30 a.m. to discuss operational and financial performance for the quarter and half-year ended September 30, 2025. Following the completion of the call, Sudeep Pharma has now submitted the audio recording to both NSE and BSE as required under Regulation 30 of the SEBI (LODR) Regulations, 2015.

Audio Recording Accessibility

The audio recording of the earnings call has been uploaded to the company's official website and is accessible to all stakeholders. The company has provided direct access to ensure transparency in investor communications.

Regulatory Compliance

Sudeep Pharma's submission dated December 22, 2025, references its earlier communications dated December 15, 2025, and December 21, 2025, regarding the earnings call intimation and investor presentation respectively. The company has maintained consistent compliance with SEBI listing regulations throughout the process.

Company Information

The pharmaceutical company operates from its registered office at 129/1/A, G.I.D.C. Estate Nandesari, Baroda-391340, Gujarat, with its corporate office located at 601, 602, 6th Floor, Sears Towers-2, Gotri-Sevasi Road, Sevasi, Vadodara-390021, Gujarat.

The submission was authorized by Dimple Mehta, Company Secretary and Compliance Officer (M.No.: F13184), demonstrating the company's adherence to corporate governance standards and regulatory requirements.

Sudeep Pharma Limited has announced its Q2 financial results, revealing significant pressure on profitability metrics despite revenue growth. The pharmaceutical company's consolidated financial performance shows margin compression across key operational parameters during the quarter.

Financial Performance Overview

The company's Q2 results demonstrate challenging operational dynamics with declining profitability metrics. While revenue maintained positive momentum, both EBITDA and net profit faced substantial pressure during the reporting period.

EBITDA Performance Analysis

Sudeep Pharma's EBITDA declined significantly to ₹55.50 crores in Q2 compared to ₹63.50 crores in the corresponding quarter of the previous year. This represents a substantial decrease of ₹8.00 crores or 12.6% on a year-on-year basis, indicating operational challenges during the quarter.

Margin Compression Trends

The company's EBITDA margin contracted sharply to 34.09% in Q2 from 42.66% in the same quarter last year. This margin compression of 857 basis points reflects significant pressure on operational efficiency and cost management, despite the company's ability to grow its top-line revenue.

Revenue and Profitability Dynamics

Sudeep Pharma achieved revenue growth of 6.7% to ₹162.80 crores from ₹152.60 crores year-on-year. However, the company struggled to maintain profitability levels. The consolidated net profit declined to ₹45.70 crores compared to ₹48.70 crores in the previous year, representing a 6.2% decrease.

Key Financial Highlights

The Q2 results underscore the challenges facing the pharmaceutical company in maintaining operational efficiency amid revenue expansion. The significant EBITDA decline and margin compression suggest increased operational costs or pricing pressures that have impacted the company's profitability metrics during this reporting period.